Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment for the MDS sub-study Meeting Abstract


Authors: DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; Arellano, M. L.; Erba, H. P.; Pigneux, A.; Stuart, R. K.; Thomas, X.; Uy, G. L.; Lemieux, I. R.; Zhang, V.; Kapsalis, S. M.; Garcia-Manero, G.; Sallman, D. A.
Abstract Title: Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment for the MDS sub-study
Meeting Title: 9th Annual Meeting of the Society of Hematologic Oncology (SOHO)
Keywords: clinical trial; myelodysplastic syndrome; targeted therapy; mds; isocitrate dehydrogenase 1; ivosidenib
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 21
Issue: Suppl. 1
Meeting Dates: 2021 Sep 8-11
Meeting Location: Virtual event
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2021-09-01
Start Page: S346
End Page: S347
Language: English
ACCESSION: WOS:000691910500243
PROVIDER: wos
DOI: 10.1016/s2152-2650(21)01805-x
Notes: Meeting Abstract: MDS-335 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein